|Description||Pioglitazone is a PPAR agonist that exhibits antidiabetic activity in patients with type 2 diabetes mellitus. It has no effect on type 1 diabetes.|
|B0084-081675||5 g||$248||In stock|
|B0084-081675||10 g||$448||In stock|
|Appearance||White to Off-white Solid|
GW501516 is a potent and highly selective PPARβ/δ agonist, with EC50 of 1 nM, with 1000-fold selectivity over hPPARα and hPPARγ. Phase 4.
CS-7017 monohydrate is a peroxisome proliferator activated receptor gamma (PPAR) agonist. It is a potential therapy for thyroid cancer and liposarcoma. It is al...
Lanifibranor is a peroxisome proliferator-activated receptors (PPAR) agonist.
Elafibranor is an agonist of the peroxisome proliferator-activated receptor-α and peroxisome proliferator-activated receptor-δ. It induces resolution of nonalco...
The dihydrochloride salt form of DG-172, a piperazin drrivative, is a PPARβ/δ inverse agonist that could promote cell differentiation of dendritic induced by GM...
In vitro, the IC50 for growth inhibition is approximately 0.8 nM while anaplastic thyroid carcinoma (ATC) tumor growth was inhibited three- to fourfold in nude ...
Inolitazone is an orally bioavailable PAPR-gamma inhibitor with potential antineoplastic activity. Inolitazone binds to and activates peroxisome proliferation-a...
Tesaglitazar is a dual-acting agonist of PPARα/γ (IC50 = 0.35 and 3.8 μM for PPARγ and PPARα, respectively). It reduces insulin resistance in obese Zucker rats ...